Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515749 | 0.88 | CYP19A1 (0.40) | CYP19A1MAOBKDM4EADORA3AR | |
| SCHEMBL877715 | 0.80 | PBRM1 (0.43) | CYP19A1AR | |
| SCHEMBL8536910 | 0.80 | PBRM1 (0.43) | CYP19A1AR | |
| SCHEMBL8531188 | 0.80 | PBRM1 (0.43) | CYP19A1AR | |
| SCHEMBL9882136 | 0.80 | PBRM1 (0.43) | CYP19A1AR | |
| SCHEMBL8537261 | 0.80 | PBRM1 (0.43) | CYP19A1AR | |
| SCHEMBL15287877 | 0.73 | ADORA3 (0.36) | CYP19A1MAOBKDM4EADORA3AR | |
| SCHEMBL25079067 | 0.72 | CYP19A1 (0.50) | CYP19A1MAOBSIGMAR1 | |
| SCHEMBL877529 | 0.70 | ADORA3 (0.33) | CYP19A1MAOBKDM4EADORA3AR | |
| SCHEMBL892210 | 0.69 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |